Goedel-Meinen L, Hofmann M, Schmidt G, Barthel P, Baedeker W, Blömer H
I. Medizinische Klinik der Technischen Universität München.
Herz. 1988 Jun;13(3):188-96.
This study was designed to determine which parameters in the signal-averaged ECG are subject to the influence of class I antiarrhythmic agents and whether the effects on these parameters differ with respect to the various subgroups of agents within the class I antiarrhythmics. For this purpose, disopyramide was chosen as representative of class Ia, tocainide Ib and flecainide Ic. A total of 23 patients, twelve with coronary artery disease and eleven with dilated cardiomyopathy and high grade ventricular arrhythmics, received randomized and single-blind, placebo-controlled high single oral doses of 300 mg disopyramide, 800 mg tocainide and 300 mg flecainide with a washout period of five half-times of the antecedent drug prior to the subsequent agent. Before and two hours after the respective drugs the signal-averaged ECG was recorded. The position of the electrodes was unchanged throughout the study. A total of 142 recordings were performed. Computerized calculation of the duration and mean voltage of the entire filtered QRS complex and the voltage during the last 40 and 50 ms, respectively, was carried out according to the method of Simson. Additionally, according to a modification by Karbenn, the duration and voltage of late potentials were analyzed. In the baseline signal-averaged ECG, 13 of 23 patients (57%) had late potentials. Of the 18 patients who received disopyramide, ten had late potentials before and after the drug. In seven, late potentials were not present either before or after the drug. In one patient with a negative finding at baseline, late potentials were observed after disopyramide. There was a significant increase in the duration (p less than 0.001) as well as a decrease in the voltage of the entire filtered QRS-complex (p less than 0.01) and the voltage during the last 40 and 50 ms, respectively (p less than 0.05). Late potentials were present before and after tocainide in nine of 18 patients (50%) who received this drug. In the remaining 50%, late potentials were not observed either before or after the drug. Comparison of mean values before and two hours after 800 mg tocainide showed no significant changes for duration or voltage of the entire filtered QRS-complex nor for the voltage during the last 40 and 50 ms, respectively. Before and after flecainide, eight of 17 patients had late potentials (47%).(ABSTRACT TRUNCATED AT 400 WORDS)
本研究旨在确定信号平均心电图中的哪些参数受I类抗心律失常药物的影响,以及这些参数的影响在I类抗心律失常药物的各个亚组之间是否存在差异。为此,选择丙吡胺作为Ia类的代表,妥卡尼作为Ib类的代表,氟卡尼作为Ic类的代表。共有23例患者,其中12例患有冠状动脉疾病,11例患有扩张型心肌病并伴有高度室性心律失常,接受了随机单盲、安慰剂对照的高单次口服剂量,分别为300mg丙吡胺、800mg妥卡尼和300mg氟卡尼,在服用后续药物之前有一个相当于前一种药物五个半衰期的洗脱期。在服用各自药物之前和之后两小时记录信号平均心电图。在整个研究过程中电极位置保持不变。总共进行了142次记录。根据Simson方法对整个滤波后的QRS波群的持续时间和平均电压以及最后40ms和50ms期间的电压进行计算机化计算。此外,根据Karbenn的修改方法,分析了晚电位的持续时间和电压。在基线信号平均心电图中,23例患者中有13例(57%)有晚电位。在接受丙吡胺治疗的18例患者中,10例在用药前后均有晚电位。7例患者在用药前后均未出现晚电位。1例基线检查结果为阴性的患者在服用丙吡胺后出现了晚电位。整个滤波后的QRS波群的持续时间显著增加(p<0.001),其电压以及最后40ms和50ms期间的电压分别降低(p<0.01和p<0.05)。在接受妥卡尼治疗的18例患者中,9例(50%)在用药前后均有晚电位。其余50%的患者在用药前后均未观察到晚电位。比较800mg妥卡尼服用前和服用后两小时的平均值,整个滤波后的QRS波群的持续时间或电压以及最后40ms和50ms期间的电压均无显著变化。在服用氟卡尼前后,17例患者中有8例(47%)有晚电位。(摘要截选至400字)